-transparent.png){kind=logo}
Eperisone Hydrochloride was launched in Japan in 1983 and has been used to improve muscle tone and treat spastic paralysis (Originator: Eisai Co., Ltd.). However, its biochemical mechanism of action is unknown. SB Drug Discovery was used to evaluate purinergic P2X (P2X) receptor antagonism using fluorescence. In this study, we discovered that its target protein is the P2X7 receptor. Also, P2X receptor subtype selectivity was high. This finding demonstrates the (Eperisone-P2X7-pain linkage), the validity of P2X7 as a drug target, and the possibility of drug repositioning of Eperisone Hydrochloride.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Makoto Okada, and
Takashi Nose
June 1992,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Makoto Okada, and
Takashi Nose
January 1992,
Functional neurology,
Makoto Okada, and
Takashi Nose
March 1997,
Japanese journal of pharmacology,
Makoto Okada, and
Takashi Nose
June 2011,
European journal of drug metabolism and pharmacokinetics,
Makoto Okada, and
Takashi Nose
January 1972,
The Journal of clinical pharmacology and new drugs,
Makoto Okada, and
Takashi Nose
January 2024,
Clinical therapeutics,
Makoto Okada, and
Takashi Nose
July 2004,
Pharmacology,
Makoto Okada, and
Takashi Nose
April 2000,
Bioorganic & medicinal chemistry letters,
Makoto Okada, and
Takashi Nose
March 1987,
European journal of pharmacology,
Makoto Okada, and
Takashi Nose
September 2022,
Biomolecules,
